

	All Cohort (n=110)		Cohort TILs on metastatic site (n=57)		
Parameters	TILS Median (IQR)	p-value	TILS Median (IQR)	p-value	
Menopausal status					
Premenopausal	10 (5-15)	0.323	10 (5-15)	0.090	
Postmenopausal	10 (5-20)		10 (5-20)		
Stage at Diagnosis					
M0	10 (5-15)	0.472	10 (5-15)	0.368	
M1	10 (5-20)		12.5 (5-20)		
Neoadjuvant chemotherapy					
No	10 (5-20)	0.306	10 (5-17.5)	0.534	
Yes	10 (5-15)		10 (5-15)		
ER status					
Negative	10 (6.3-15)	0.083	10 (5-15)	0.788	
Positive	10 (5-15)		10 (5-20)		
PR status					
Negative	10 (5-15)	0.279	10 (5-15)	0.836	
Positive	10 (4-15)		10 (2.5-20)		
HR status*					
Negative	10 (6-15)	0.080	10 (5-15)	0.788	
Positive	10 (5-15)		10 (5-20)		
HER2 status					
2+	10 (5-15)	0.889	10 (5-17.5)	0.151	
3+	10 (5-15)		10 (5-15)		
Visceral Disease					
Yes	10 (5-15)	0.048	10 (5-11.3)	0.428	
No	15 (5-20)		15 (5-15)		
Brain Disease					
Yes	15 (10-15)	0.383	5 (3.5-10)	0.444	
No	10 (5-15)		10 (5-15)		
Site of TILS evaluation					
Metastatic site	10 (5-15)	0.590	Liver	5 (5-10)	0.0313
			Lung	15 (10-30)	
			Lymph node	12.5 (2.8-18.8)	
			Soft Tissue	10 (5.0-16.3)	
			Bone	7.5 (3.8-11.3)	
Primary BC	10 (5-15)		//		
Best response					
Complete response	12.5 (8.8-15)	0.554	10 (7.5-15)	0.148	
Partial Response	10 (5-15)		7.5 (5-15)		
Stable Disease	10 (5-20)		10 (5-20)		
Progression Disease	10 (10-15)		2 (2-2)		
Alive status					
Alive	10 (5-15)	0.088	10 (5-15)	0.010	
Dead	5 (5-15)		5 (2.8-10)		

Table 2 Correlations Between TILS (Continuous) And Clinical Pathological Characteristics. On the left the whole cohort and on the right the cohort of patients whose TILs were evaluated at the metastatic site.

*HR: HR+ i.e. ER or PR positive

Abbreviations: BC, breast cancer; ER: estrogen receptor; HR: hormone receptor; IQR: interquartile range; PR: progesterone receptor; TILs: tumor-infiltrating lymphocytes.